论文部分内容阅读
为了观察ＣＤ３ＡＫ细胞对原发性肝癌（简称肝癌）患者免疫功能的影响。采用ＣＤ３ＡＫ细胞治疗６５例不能切除的肝癌患者，分别于治疗前后测定患者Ｔ细胞亚群（ＡＰＡＡＰ法）和血清可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）水平（ＥＬＩＳＡ法）。结果：ＣＤ３ＡＫ细胞治疗后肝癌患者Ｔ细胞亚群ＣＤ＋３、ＣＤ＋４、ＣＤ＋８升高，ｓＩＬ－２Ｒ水平下降，统计学有显著性差异（Ｐ＜０．０５）。提示ＣＤ３ＡＫ细胞治疗肝癌对提高患者免疫功能有积极作用
In order to observe the effect of CD3AK cells on the immune function of patients with primary liver cancer (abbreviated as liver cancer). CD3AK cells were used to treat 65 unresectable patients with hepatocellular carcinoma. The T-cell subsets (APAAP method) and serum soluble interleukin-2 receptor (sIL-2R) levels (ELISA) were determined before and after treatment. RESULTS: After treatment with CD3AK cells, the T cell subpopulations CD+3, CD+4, and CD+8 were increased and the sIL-2R levels were decreased in patients with hepatocellular carcinoma. There was a statistically significant difference (P<0.05). Prompt that CD3AK cells have a positive effect on improving the immune function of patients with liver cancer